Just looked at ANTH chart for last 1 year and 5 years. I see in last 1 year, it went from $4 to $10 and now came back to less than $3. Don's see jump of 800% ever.
I think companies go to Phase 3 only after it meets primary end points in Phase 2? is my understanding correct? because if this drug was failed in past, then I believe FDA should have never agree on staring phase 3 with SPA, correct?
What is that 180M cash they shown in balance sheet? is that a made up number?